Actavis
Actavis buys Allergan for $66 billion
November 18, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Canada, Valeant, merger
The stately dance between Actavis and Allergan has culminated in the former buying the Botox manufacturer in a $66 billion …
Actavis appoints Pepsi head as CFO amid takeover talk
November 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, maria moen, pepsi
Dublin-based speciality pharma firm Actavis which is currently in talks to buy Allergan for $60 billion, has hired a chief …
Allergan eyeing Actavis buyout
November 13, 2014Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Botox, Valeant, acquisition, buyout, merger
Allergan is attempting to block a recent Valeant hostile takeover bid by seeking the rumoured alternative merger deal with Actavis, …
Perrigo acquires Omega for $4.5 billion
November 7, 2014Manufacturing and Production, Sales and Marketing Actavis, Boehringer Ingelheim, Boehringer Ingelheim., Elan, Perrigo, Sanofi, omega
In a deal worth $4.5 billion Perrigo has announced the acquisition of over-the-counter (OTC) drugmaker Omega. This places the Irish …
Allergan and Valeant trade blows as shareholder meeting looms
November 6, 2014Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner
Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …
ABPI and BIA establish new manufacturing partnership
September 23, 2014Manufacturing and Production, Sales and Marketing ABPI, Actavis, AstraZeneca, BIA, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, Knowledge Transfer Network (KTN), Oxford BioMedica, Pfizer, Whitehead, bates, mmip
The ABPI and the Bioindustry Association (BIA) have jointly established a new Medicines Manufacturing Industry Partnership (MMIP) to boost medicines …
Forest sold to Actavis for $25 billion
February 18, 2014Sales and Marketing Actavis, CNS, Forest, acquisition, labs, merger, synergy
The rumours of a substantial deal for Forest have been proven true after Actavis announced this afternoon that it will …
Danish government: ‘Sue pharma firms’
January 23, 2014Sales and Marketing Actavis, Danish, Denmark, Lundbeck, celexa
A senior figure in Denmark’s government has said that local authorities should take legal action against pharma firms which put …
Actavis makes Aurobindo sale
January 21, 2014Sales and Marketing Actavis, Aurobindo, India, generics
Actavis is to sell its commercial operations in seven European countries to Aurobindo Pharma in a bid to put more …
Actavis: China is ‘too risky’
January 17, 2014Sales and Marketing Actavis, China, bribery, generics, risky
The boss of generic drug manufacturer Actavis says his company is pulling out of China because the business environment there …
Pharma facility news in brief
November 18, 2013Manufacturing and Production Actavis, Bend Research and WuXi PharmaTech, China Pharma, GlaxoSmithKline, manufacturing, nibs
GlaxoSmithKline is planning to boost in-house production of pharmaceuticals in India by building a brand new facility with an investment …
Actavis snaps up Warner Chilcott
May 22, 2013Research and Development, Sales and Marketing Actavis, Warner Chilcott
Actavis is to buy Dublin-based firm Warner Chilcott in an $8.5 billion deal which will see the Warner name disappear …
Actavis to invest in Florida facility
March 25, 2013Manufacturing and Production Actavis, Watson
Actavis has announced a $40.5 million investment round at its plant in Davie, Florida, that looks set to create around …
Pharma manufacturing news in brief
March 11, 2013Business Services, Manufacturing and Production Actavis, DSM, Eisai, J&J, JJ, Marken, SAFC, Sagent Pharma
Actavis revises supply deal with Sagent, facility updates from Marken and SAFC, a supply deal for DSM plus another J&J …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
